A recent Mercer study showed that employers pulled back on GLP-1 weight-loss medication coverage in 2026, with more cuts considered for 2027
How does oral BPC-157 compare to injectable BPC-157
Some research indicates that tirzepatide's direct metabolic effects on liver and fat tissue function may improve lipid profiles even beyond what weight reduction alone would achieve, suggesting a dual benefit for heart health
As the popularity of GLP-1 drugs fof weight loss continues to grow, understanding the short- and long-term side effects of these medications is just as important as measuring pounds lost on a scale
Employer Implications As oral nonpeptide GLP1s and combination therapies approach market entry, plan sponsors should anticipate expanded utilization, increased clinical complexity and heightened pressure on costcontainment strategies
Regular follow-up with your healthcare team allows for ongoing assessment and adjustment of your treatment plan